Newsmeme!
Discover News you didn't know existed
Tolerability Testing
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Published July 5, 2009, 8:14 pm, redOrbit
EMERYVILLE, Calif. and HUENENBERG, Switzerland, July 5 /PRNewswire-FirstCall/ -- Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc.
Alcon Commences Phase 2 Clinical Trial of NovaBays NVC-422 for Viral Conjunctivitis
Published July 5, 2009, 3:14 pm, Finanzen.net
Alcon, Inc. (NYSE: ACL ) ...
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Published July 5, 2009, 3:00 pm, PR Newswire via Yahoo! Finance
Alcon, Inc. and its partner, NovaBay Pharmaceuticals, Inc. , announced today that Alcon has begun treating patients in a Phase 2 clinical trial of NovaBay's patented lead Aganocide® compound, NVC-422, for viral conjunctivitis, a type of "pink eye".
Gefitinib Receives European Licence For The Treatment Of Lung Cancer For Patients With EGFR Activating Mutation ...
Published July 2, 2009, 6:23 am, Medical News Today
AstraZeneca announced that it has received a licence by the European Medicines Agency (EMEA) for its oral targeted anti-cancer drug, gefitinib, for EGFR (epidermal growth factor receptor-tyrosine kinase) activating mutation positive patients with Non Small Cell Lung Cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for 80% of all lung cancer cases.
Myriad Pharmaceuticals, Inc. Established As An Independent Pharmaceutical Development Company
Published July 2, 2009, 2:48 am, PharmaceuticalOnline
Myriad Pharmaceuticals, Inc. (MPI) today announced that it has completed its previously announced spin-off from Myriad Genetics, Inc. as of 11:59 p.m. last evening.
Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development ...
Published July 1, 2009, 5:21 am, Marketwire
BUFFALO, NY--(Marketwire - July 1, 2009) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Product Management Office (CBMS-MITS JPMO) of The Department of Defense (DoD) has exercised the contract option and released a second phase of funding under a contract calling for developmental studies ...
Biolex Therapeutics Announces Completion Of Enrollment In SELECT-2 Phase 2b Trial Of Locteron(R) In Chronic Hepatitis C
Published June 30, 2009, 3:09 am, Medical News Today
Biolex Therapeutics, Inc. announced that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C.
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic Hepatitis C
Published June 29, 2009, 6:54 am, Marketwire
PITTSBORO, NC--(Marketwire - June 29, 2009) - Biolex Therapeutics, Inc. announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |